Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapy.

Abstract

Among shigellas isolated from patients in England and Wales in 2002, 10% of subgroups A, B and C, and 13% of subgroup D (Shigella sonnei), were resistant to nalidixic acid. As a consequence, should antimicrobial therapy be indicated, the efficacy of nalidixic acid as the preferred treatment for children with bacillary dysentery has been jeopardised.

• Authors: T Cheasty, M Day, E J Threlfall
• Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Clin Microbiol Infect) Vol. 10 Issue 11 Pg. 1033-5 (Nov 2004) ISSN: 1198-743X [Print] England
• PMID: 15522014 (Publication Type: Journal Article)

Chemical References

• Anti-Infective Agents
• Nalidixic Acid

Topics

• Adult
• Anti-Infective Agents (pharmacology, therapeutic use)
• Child
• Drug Resistance, Bacterial
• Dysentery, Bacillary (drug therapy, epidemiology, microbiology)
• England (epidemiology)
• Humans
• Microbial Sensitivity Tests
• Nalidixic Acid (pharmacology, therapeutic use)
• Shigella (drug effects)
• Shigella sonnei (drug effects)
• Wales (epidemiology)